Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04775550 · ClinicalTrials.gov registry record · Phase 2

DARA RVD For High Risk SMM

A Phase 2 study of Multiple Myeloma and High-risk Smoldering Multiple Myeloma, sponsored by Omar Nadeem, MD.

Active
Registry status
Phase 2
Development phase
61
Enrollment target
6
Study locations

NCT04775550 is a Phase 2 study of Multiple Myeloma and High-risk Smoldering Multiple Myeloma that is active but no longer recruiting, run by Omar Nadeem, MD. The registered enrollment target is 61 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04775550, a Phase 2 study of Multiple Myeloma and High-risk Smoldering Multiple Myeloma, is active but no longer recruiting, sponsored by Omar Nadeem, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
61 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma. The names of the study drugs involved in this study are: * Daratumumab (also called Darzalex Faspro) * Bortezomib (also called Velcade) * Lenalidomide (also called Revlimid) * Dexamethasone

Conditions Studied

Multiple Myeloma High-risk Smoldering Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab
  • DRUG Bortezomib

Study Locations (6)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • Dana-Farber Brigham Cancer Center - Foxborough - Foxborough
  • Dana-Farber Cancer Institute - Merrimack Valley - Methuen
  • Dana-Farber Brigham Cancer Center - South Weymouth

Connecticut

  • Stamford Hospital - Stamford

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2021-03-08
Est. Completion 2030-12-08
Phase Phase 2

Sponsor

Omar Nadeem, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04775550

The ClinicalTrials.gov registry entry for NCT04775550 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The listed sponsor is Omar Nadeem, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT04775550 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Connecticut.

Frequently Asked Questions

What is clinical trial NCT04775550 about?

NCT04775550 is a clinical study titled "DARA RVD For High Risk SMM". The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma. The names ...

What is the current status of trial NCT04775550?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2021-03-08. Estimated completion is 2030-12-08.

What conditions does trial NCT04775550 study?

This clinical trial studies the following conditions: Multiple Myeloma, High-risk Smoldering Multiple Myeloma.

What interventions are being tested in trial NCT04775550?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT04775550?

This trial is sponsored by Omar Nadeem, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04775550 being conducted?

This trial has 6 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

High-risk Smoldering Multiple Myeloma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.